Brokers Offer Predictions for Trevi Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:TRVI)

Trevi Therapeutics, Inc. (NASDAQ:TRVIFree Report) – Analysts at Leerink Partnrs raised their FY2025 earnings estimates for Trevi Therapeutics in a research note issued to investors on Wednesday, March 20th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($0.60) per share for the year, up from their previous estimate of ($0.61). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.39) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.64) EPS.

TRVI has been the subject of several other reports. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Thursday, March 21st. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target on shares of Trevi Therapeutics in a research note on Thursday, March 21st.

Get Our Latest Analysis on Trevi Therapeutics

Trevi Therapeutics Stock Up 1.2 %

TRVI opened at $3.39 on Monday. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The company has a fifty day simple moving average of $2.33 and a 200 day simple moving average of $1.86. The stock has a market cap of $233.77 million, a P/E ratio of -11.69 and a beta of 0.85.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TRVI. Vanguard Group Inc. grew its position in shares of Trevi Therapeutics by 7.6% in the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company’s stock valued at $336,000 after acquiring an additional 10,780 shares during the period. State Street Corp bought a new position in shares of Trevi Therapeutics during the 1st quarter worth approximately $81,000. Virtu Financial LLC bought a new position in Trevi Therapeutics during the first quarter worth $44,000. FMR LLC bought a new position in Trevi Therapeutics during the second quarter worth $234,000. Finally, Northern Trust Corp boosted its position in Trevi Therapeutics by 305.6% during the second quarter. Northern Trust Corp now owns 46,298 shares of the company’s stock worth $130,000 after purchasing an additional 34,884 shares during the period. 95.76% of the stock is currently owned by institutional investors.

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

See Also

Earnings History and Estimates for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.